Skip to main content

Table 1 Basic Characteristics of the Study Population (n = 1136)

From: Serum uri acid: neuroprotection in thrombolysis. The Bergen NORSTROKE study

 

rt-PA

Non rt-PA

Late

p

Sample size, n

186

261

689

 

Time to blood sample, h (IR)

1.5 (1.0-2.4)

1.9 (1.4-2.7)

18.7 (9.3-31.1)

 

Age, years (SD)

69.3 (± 14.2)

70.9 (± 14.1)

71.4 (± 14.6)

0.21

Male Sex, n (%)

118 (63.4)

149 (57.1)

385 (± 55.9)

0.17

Median NIHSS day 0* (IR)

9.5 (4-17)

3 (1-5)

3 (1-7)

0.0001

NIHSS day 0, n (%)

   

0.0001

   < 8

76 (40.9)

216 (82.7)

524 (76.1)

 

   8-14

42 (22.6)

13 (7.3)

78 (11.3)

 

   > 14

68 (36.5)

26 (10.0)

87 (12.6)

 

SUA levels, μmol/L, n (%)

   

0.2

   < 305

56 (29.5)

93 (34.7)

257 (33.5)

 

   305-399

63 (33.2)

100 (37.3)

249 (32.5)

 

   ≥ 400

71 (37.4)

75 (28.0)

260 (34.0)

 

Creatinine, μmol/L, n (%)

   

0.4

   < 120

169 (91.0)

247 (92.1)

687 (89.7)

 

   ≥ 120

17 (9.0)

21 (7.9)

79 (10.3)

 

SBP day 0, mmHg (SD)

162.0 (± 25.9)

168.5 (± 29.3)

167.5 (± 33.6)

0.05

Previous diseases, n (%)

    

   Hypertension

92 (49.5)

133 (50.0)

415 (54.6)

0.3

   Diabetes

23 (12.4)

33 (12.6)

119 (15.8)

0.3

   Stroke

21 (11.0)

58 (21.7)

145 (19.1)

0.01

   TIA

18 (9.4)

28 (10.5)

71 (9.3)

0.8

Median mRS day 7 (IR)

2 (1-4)

2 (1-3)

2 (1-4)

0.01

  1. IR, Interquantile Range; SD, Standard Deviation; NIHSS, National Institutes of Health Stroke Scale; SUA, serum Uric Acid; SBP, systolic blood pressure; TIA, transient ischemic attack; mRS, modified Rankin Scale
  2. *Day 0: day of admission